Therapy Detail

Therapy Name Atezolizumab + Carboplatin + Pemetrexed
Synonym
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Atezolizumab Tecentriq RG7446|MPDL3280A Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 50 Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in patients with advanced urothelial carcinoma, metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, in combination with bevacizumab, paclitaxel, and carboplatin for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound for advanced or metastatic triple-negative breast cancer expressing PD-L1, and in combination with carboplatin and etoposide for small cell lung cancer (FDA.gov).
Carboplatin Paraplatin CBDCA Chemotherapy - Platinum 6 Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).
Pemetrexed Alimta LY231514 Chemotherapy - Antimetabolite 10 Alimta (pemetrexed) is an antifolate, which inhibits thymidylate synthase (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT01633970 Phase I Atezolizumab + Carboplatin + Paclitaxel Atezolizumab + Carboplatin + Pemetrexed Atezolizumab + Bevacizumab + Capecitabine A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors Active, not recruiting
NCT03337698 Phase Ib/II Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + CPI-444 Atezolizumab Atezolizumab + Docetaxel Docetaxel Atezolizumab + Cobimetinib Atezolizumab + Carboplatin + Pemetrexed Atezolizumab + RO6958688 A Study Evaluating ThA Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus Lung) Recruiting